Clinical Study

A5415 A Limited-Center, Prospective, Double-Blind, Placebo-Controlled Study To Evaluate The Effects Of Cenicriviroc Mesylate On Arterial Inflammation In People Living With Hiv

Posted Date: Apr 25, 2023

  • Investigator: Moises Huaman
  • Specialties:
  • Type of Study: Drug

A Limited-Center, Prospective, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living with HIV

Criteria:

Have Hiv Infection Current Hiv Rna <20 Current Cd4+ >200 On Stable Antiretroviral Therapy No Myocardial Infarction Or Unstable Angina Within 90 Days Hepatitis C Negative No Untreated Hepatitis B No Active Malignancy (Cancer) No Change In Statin Therapy For 90 Days No History Of Radiation Therapy Not Currently Pregnant, Planning To Become Pregnant Or Breastfeeding.

Keywords:

Hiv, Inflammation

For More Information:

Michelle Saemann
513-584-2245
saemanmd@ucmail.uc.edu


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.